The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of infiltrating T cell subtypes on survival and response to FLOT chemotherapy in resectable oesophagogastric adenocarcinoma (OGA).
 
Avani Athauda
No Relationships to Disclose
 
Tatiany Silveira
No Relationships to Disclose
 
Thomas Lund
No Relationships to Disclose
 
Katharina von Loga
No Relationships to Disclose
 
Benjamin Challoner
No Relationships to Disclose
 
Isma Rana
No Relationships to Disclose
 
Janet Thomas
No Relationships to Disclose
 
Naureen Starling
Honoraria - Amgen; GlaxoSmithKline; GlaxoSmithKline; Lilly; Lilly; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; Novartis; Pierre Fabre; Pierre Fabre; Pierre Fabre; Seagen; SERVIER; SERVIER; SERVIER
Consulting or Advisory Role - AstraZeneca; MSD; MSD Oncology; Novartis Pharmaceuticals UK Ltd.; Pfizer
Research Funding - AstraZeneca (Inst); BMS (Inst); Pfizer/EMD Serono (Inst)
Travel, Accommodations, Expenses - Guardant Health; MSD Oncology
(OPTIONAL) Uncompensated Relationships - Guardant Health
 
Ian Chau
Honoraria - Eisai; Lilly; Roche/Genentech; SERVIER
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; OncXerna Therapeutics; Roche/Genentech; Seagen; SERVIER; Sotio; Taiho Oncology; Turning Point Therapeutics
Research Funding - Janssen-Cilag (Inst); Lilly (Inst)
 
Sheela Rao
Consulting or Advisory Role - Bayer; Roche
Travel, Accommodations, Expenses - Bayer; Incyte; SERVIER
 
David J. Watkins
No Relationships to Disclose
 
David Cunningham
Stock and Other Ownership Interests - OVIBIO
Consulting or Advisory Role - OVIBIO
Research Funding - 4SC (Inst); Bayer (Inst); Celgene (Inst); Clovis Oncology (Inst); Leap Oncology (Inst); Lilly (Inst); MedImmune (Inst); Roche (Inst)
 
Marco Gerlinger
Stock and Other Ownership Interests - Vertex
Research Funding - Bristol myers squibb; Merck; Roche/Genentech